Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM1 | P23921 | 2/20 | 1.00 |
| ▸ | RRM2B | Q7LG56 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | SCD | O00767 | 1/20 | 0.55 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.54 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.54 |
| ▸ | TOP1 | P11387 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | ALPG | P10696 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036572 | 0.90 | RRM1 (1.00) | RRM1RRM2BMEN1KMT2AGAA | |
| SCHEMBL10036568 | 0.83 | RRM1 (0.71) | RRM1RRM2BMEN1POLBKMT2A | |
| SCHEMBL11137540 | 0.82 | RRM1 (0.70) | RRM1RRM2BMEN1POLBKMT2A | |
| SCHEMBL10002070 | 0.79 | RRM1 (0.65) | RRM1RRM2BMEN1KMT2AMAPT | |
| SCHEMBL3597550 | 0.78 | RRM1 (0.64) | RRM1RRM2BMEN1POLBKMT2A | |
| SCHEMBL12248965 | 0.78 | PARP1 (0.65) | RRM1RRM2BMEN1KMT2AMAPT | |
| SCHEMBL18425638 | 0.78 | RRM1 (0.63) | RRM1RRM2BMEN1POLBKMT2A | |
| SCHEMBL18425097 | 0.78 | ADORA3 (0.69) | RRM1RRM2BMEN1POLBKMT2A | |
| SCHEMBL18426009 | 0.78 | RRM1 (0.62) | RRM1RRM2BMEN1POLBKMT2A | |
| SCHEMBL12249017 | 0.77 | RRM1 (0.62) | RRM1RRM2BMEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190161461-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2019-05-30 | — | — | US | disclosed |
| EP-2809662-B1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | HOPE CITY (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20180155303-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2018-06-07 | — | — | US | disclosed |
| US-9796692-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170137392-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2017-05-18 | — | — | US | disclosed |
| US-9598385-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160122308-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2016-05-05 | — | — | US | disclosed |
| US-9126960-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150087844-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2015-03-26 | — | — | US | disclosed |
| US-RE45020-E1 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2014-07-15 | — | — | US | disclosed |
| WO-2013116765-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE (US) | 2013-08-08 | — | — | WO | disclosed |
| US-8372983-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120253048-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2012-10-04 | — | — | US | disclosed |
| US-8163783-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110245304-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2011-10-06 | — | — | US | disclosed |
| US-7956076-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2011-06-07 | — | — | US | disclosed |
| US-7956076-B2 | Ribonucleotide reductase inhibitors and methods of use | CITY OF HOPE (US) | 2011-06-07 | — | — | US | disclosed |
| US-20090258915-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2009-10-15 | — | — | US | disclosed |
| US-20090258915-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | CITY OF HOPE | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087844-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | RRM1 3/4885RRM2B 2/4885MEN1 4259/4885 |
| US-20160122308-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | RRM1 3/4885RRM2B 2/4885MEN1 4259/4885 |
| US-20090258915-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | RRM1 3/4885RRM2B 2/4885MEN1 4435/4885 |
| US-20180155303-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | RRM1 3/4885RRM2B 2/4885MEN1 4259/4885 |
| US-20170137392-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | RRM1 3/4885RRM2B 2/4885MEN1 4259/4885 |
| US-20120253048-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | RRM1 3/4885RRM2B 2/4885MEN1 4259/4885 |
| US-20110245304-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | RRM1 3/4885RRM2B 2/4885MEN1 4435/4885 |
| US-20190161461-A1 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE | RRM2, RRM2B, RRM1 | RRM1 3/4885RRM2B 2/4885MEN1 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.